Please login to the form below

tenofovir

This page shows the latest tenofovir news and features for those working in and with pharma, biotech and healthcare.

MSD claims EU approval for two HIV products

The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,

Latest news

GSK’s says depot HIV injection works over three years

drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
Janssen’s single tablet Symtuza gains NHS England funding

Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]).is once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV-1 infection in adults and adolescents aged ... Biktarvy is a combination of integrase
ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy
GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
Gilead’s Biktarvy gets European approval, setting up battle with GSK

The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

More from news
Approximately 9 fully matching, plus 85 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
Pharma deals during July 2012

Merck has licensed CMX 157 an oral nucleoside reverse transcriptase inhibitor for treatment of HIV that is 200-fold more potent in vitro than tenofovir (Gilead's product with sales of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

World AIDS Day 2018: Fighting the stigma surrounding HIV

10. Tenofovir – a nucleotide reverse transcriptase inhibitor (NtRTI). 11. Acts as a nucleotide analogue that competitively inhibits reverse transcriptase, the enzyme required for replication of the viral genome.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Medical Writer: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Manager: Competitive Salary Offered

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Manager / Account Director: Competative

Account Director, Medical Education: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Business Director: Competitive Salary Offered

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Senior Medical Writer: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Global Business Development Director – Health Education: excellent commission

Account Director: Competitive Salary Offered

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Associate Director: £75, 000-90, 000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Subscribe to our email news alerts

PMHub

Add my company

Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...